Chemo Pharma Laboratories Ltd Stock Price Today (NSE: CHEMOPH)
Fundamental Score
Chemo Pharma Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chemo Pharma Laboratories Ltd share price today is ₹109.00, up +0.00% on NSE/BSE as of 30 March 2026. Chemo Pharma Laboratories Ltd (CHEMOPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹15.02 (Cr). The 52-week high for CHEMOPH share price is ₹152.00 and the 52-week low is ₹95.00. The company has a Return on Equity (ROE) of 3.47% and a debt-to-equity ratio of 0.01.
Chemo Pharma Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Chemo Pharma Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Chemo Pharma Laboratories Share Price: A Growth Strategy Perspective
A key trend in the pharmaceutical industry is the increasing focus on specialized generics and niche therapeutic areas. This presents both an opportunity and a challenge for companies like Chemo Pharma Laboratories Ltd. Currently trading at ₹137.300003, the lack of a Price-to-Earnings (PE) ratio for Chemo Pharma Laboratories share price suggests potential challenges in profitability or recent financial performance. This preliminary analysis will delve into key financial metrics to understand the company's competitive positioning and growth potential.
One crucial aspect is the company's Return on Capital Employed (ROCE) of 5.17%. This figure indicates the efficiency with which Chemo Pharma Laboratories Ltd. utilizes its capital to generate profits. A low ROCE can significantly impact the company's ability to build a strong economic moat. Compared to sector leaders, this figure might suggest a weaker competitive advantage and challenges in reinvesting profits for future growth. A higher ROCE would typically signal a more robust ability to defend market share and generate shareholder value.
When examining sector peers, it's useful to look at factors beyond pure financials. For instance, comparing Chemo Pharma Laboratories Ltd with
Mankind Pharma Ltd, we can observe differences in management quality through factors like strategic decision-making, capital allocation efficiency, and investor communication. Such qualitative aspects, while difficult to quantify directly, profoundly influence long-term performance and investor confidence.The absence of a PE ratio and a relatively low ROCE necessitate a deeper dive into other financial metrics and qualitative factors, including debt levels, cash flow generation, and pipeline strength. A comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, would provide a more holistic view of Chemo Pharma Laboratories' financial health and potential investment attractiveness. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chemo Pharma Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHEMOPH across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (3.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.17%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-83.61%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (1.39% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (1.39% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-0.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (27.89%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.17%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chemo Pharma Laboratories Ltd Financial Statements
Comprehensive financial data for Chemo Pharma Laboratories Ltd including income statement, balance sheet and cash flow
About CHEMOPH (Chemo Pharma Laboratories Ltd)
Chemo Pharma Laboratories Ltd is a historical pharmaceutical entity rooted in the Indian subcontinent, specifically Mumbai. Established in 1942, the company boasts a rich legacy in... the research, development, and manufacture of pharmaceutical and bulk drug products. For decades, Chemo Pharma Laboratories Ltd played a significant role in the healthcare sector, contributing to the production of vital medications and active pharmaceutical ingredients. Their legacy is intertwined with the evolution of the pharmaceutical industry in India, having navigated changing regulatory landscapes and technological advancements during their active years. The company's historical operations involved a range of activities, from research and development to large-scale production and distribution, supporting healthcare needs across a broad spectrum. The company's journey took an interesting turn in October 2025, marking a significant shift in its identity and strategic direction. At this time, Chemo Pharma Laboratories Ltd underwent a transformation, changing its name to Starsource Multitrade Limited. This change signaled a departure from its established focus on pharmaceuticals and a move towards new ventures and opportunities. While the precise details of this transition remain subject to public information, the renaming marked a pivotal moment in the company's history, indicating a strategic realignment of its business model and objectives. The former identity as Chemo Pharma Laboratories Ltd remains a testament to its pharmaceutical past, forever etched in the annals of the Indian pharmaceutical industry. As Starsource Multitrade Limited, the company experienced a period where its operational activities became limited. While the company had a legacy in the pharmaceutical sector, Starsource Multitrade Limited did not have significant operations and was transitioning away from the active production of pharmaceutical and bulk drug products. The change was a reflection of the evolving business climate, and the company's efforts to change and adapt to new opportunities. The journey from Chemo Pharma Laboratories Ltd to Starsource Multitrade Limited encapsulates the dynamic nature of the business world, where companies must constantly reassess their strategies and navigate shifting market forces to remain relevant and competitive.
Company Details
Key Leadership
CHEMOPH Share Price: Frequently Asked Questions
What is the current share price of Chemo Pharma Laboratories Ltd (CHEMOPH)?
As of 30 Mar 2026, 11:00 am IST, Chemo Pharma Laboratories Ltd share price is ₹109.00. The CHEMOPH stock has a market capitalisation of ₹15.02 (Cr) on NSE/BSE.
Is CHEMOPH share price Overvalued or Undervalued?
CHEMOPH share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Chemo Pharma Laboratories Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of CHEMOPH share price?
The 52-week high of CHEMOPH share price is ₹152.00 and the 52-week low is ₹95.00. These values are updated daily from NSE/BSE price data.
What factors affect the Chemo Pharma Laboratories Ltd share price?
Key factors influencing CHEMOPH share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Chemo Pharma Laboratories Ltd a good stock for long-term investment?
Chemo Pharma Laboratories Ltd shows a 5-year Profit Growth of 1.39% and an ROE of 3.47%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in CHEMOPH shares.
How does Chemo Pharma Laboratories Ltd compare with its industry peers?
Chemo Pharma Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare CHEMOPH share price P/E of 0.00x and ROE of 3.47% against the industry averages to determine competitive standing.
What is the P/E ratio of CHEMOPH and what does it mean?
CHEMOPH share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is CHEMOPH performing according to Bull Run's analysis?
CHEMOPH has a Bull Run fundamental score of 1.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CHEMOPH belong to?
CHEMOPH operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Chemo Pharma Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for CHEMOPH?
CHEMOPH has an ROE of 3.47%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Chemo Pharma Laboratories Ltd generates profits from shareholders capital.
How is CHEMOPH debt-to-equity ratio and what does it indicate?
CHEMOPH has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is CHEMOPH dividend yield and is it a good dividend stock?
CHEMOPH offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Chemo Pharma Laboratories Ltd shares.
How has CHEMOPH share price grown over the past 5 years?
CHEMOPH has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 1.39%, and EPS Growth 1.39%.
What is the promoter holding in CHEMOPH and why does it matter?
Promoters hold 27.89% of CHEMOPH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Chemo Pharma Laboratories Ltd.
What is CHEMOPH market capitalisation category?
CHEMOPH has a market capitalisation of ₹15 crores, placing it in the Small-cap category.
How volatile is CHEMOPH stock?
CHEMOPH has a beta of N/A. A beta > 1 suggests the Chemo Pharma Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CHEMOPH operating profit margin trend?
CHEMOPH has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is CHEMOPH quarterly performance?
Recent quarterly performance shows Chemo Pharma Laboratories Ltd YoY Sales Growth of N/A% and YoY Profit Growth of -83.61%.
What is the institutional holding pattern in CHEMOPH?
CHEMOPH has FII holding of 0.00% and DII holding of 0.17%. Significant institutional holding often suggests professional confidence in the Chemo Pharma Laboratories Ltd stock.